Interim research management and commissioner

Considering the recent developments of HTA regulations by the European Union regarding medical technologies, innovative health care companies build HTA/HEOR capacity within their organisations, even more rapidly than before. New employees will have to be recruited and current staff will redirect their activities. In addition, pharmaceutical companies will keep developing their in-house HTA/HEOR capacity. As such, senior and executive level HTA/HEOR capacity is indispensable for any HTA development, for instance when starting a new HTA/HEOR team, setting priorities of research activities, and developing a longer term HTA/HEOR research agenda.

Like any department or unit, HTA/HEOR teams and research groups benefit from a leader who inspires, proposes how to move forward, and is a primary contact for staff members and colleagues. Furthermore, representation of HTA/HEOR within and outside the organisation is important for the success of innovative health care companies.

As a former principal investigator, department head, full professor, dean and (vice-)president of various scientific institutes and advisory organisations, I rely on extensive experience, also because of the many projects and consultancies for health care companies and nonprofit organisations. I am characterised as an inspiring and enthusiastic leader and I would be delighted to work for you as your interim HTA director or executive.